/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. OncLive® On Air
  2. S18 Ep33: Current Approaches and Future Directions for Early-Stage TNBC
S18 Ep33: Current Approaches and Future Directions for Early-Stage TNBC

S18 Ep33: Current Approaches and Future Directions for Early-Stage TNBC

OncLive® On Air · Sep 4, 2026

Experts discuss integrating ADCs and immunotherapy for high-risk, early-stage TNBC, focusing on post-neoadjuvant settings and trial selection.

Multi-Marker Classifiers Will Likely Replace Single Biomarkers for Predicting ADC Response

The difficulty in finding a single predictive biomarker for antibody-drug conjugate (ADC) efficacy suggests that complex, multi-marker classifiers, like those in the ISPY 2.2 trial, represent the future for guiding ADC therapy selection over simple IHC cutoffs.

S18 Ep33: Current Approaches and Future Directions for Early-Stage TNBC thumbnail

S18 Ep33: Current Approaches and Future Directions for Early-Stage TNBC

OncLive® On Air·2 months ago

Neoadjuvant ADC Monotherapy Is a Key De-escalation Strategy for Vulnerable Patients

For frail, elderly, or low-tumor-burden patients with early-stage TNBC, single-agent ADCs in the neoadjuvant setting are being explored to de-escalate treatment, potentially sparing them the harsh toxicities of standard multi-agent chemotherapy regimens like KEYNOTE-522.

S18 Ep33: Current Approaches and Future Directions for Early-Stage TNBC thumbnail

S18 Ep33: Current Approaches and Future Directions for Early-Stage TNBC

OncLive® On Air·2 months ago

Neoadjuvant ADC Trials Leverage Intact Tumors for Better Immunotherapy Priming

Testing antibody-drug conjugate (ADC) and immunotherapy combinations in the neoadjuvant setting is strategically superior because an intact tumor's antigen load enhances T-cell priming and immunotherapy efficacy, an advantage lost in the post-surgery adjuvant setting.

S18 Ep33: Current Approaches and Future Directions for Early-Stage TNBC thumbnail

S18 Ep33: Current Approaches and Future Directions for Early-Stage TNBC

OncLive® On Air·2 months ago

Geographic Availability, Not Drug Profile, Often Dictates Patient Enrollment in ADC Trials

In clinical practice, the choice between competing post-neoadjuvant antibody-drug conjugate (ADC) trials is often driven by the practical reality of which study is open and geographically accessible, rather than a clear biological signal suggesting one ADC is superior.

S18 Ep33: Current Approaches and Future Directions for Early-Stage TNBC thumbnail

S18 Ep33: Current Approaches and Future Directions for Early-Stage TNBC

OncLive® On Air·2 months ago

TROP2-Targeting ADCs Show Efficacy Regardless of TROP2 Expression Levels

Contrary to expectations, TROP2 expression is not a reliable predictive biomarker for response to TROP2-targeting antibody-drug conjugates (ADCs). These drugs have shown activity across various expression levels, challenging the standard biomarker-driven approach to patient selection.

S18 Ep33: Current Approaches and Future Directions for Early-Stage TNBC thumbnail

S18 Ep33: Current Approaches and Future Directions for Early-Stage TNBC

OncLive® On Air·2 months ago

Oral PARP Inhibitors Emerge as a Neoadjuvant Chemo-Free Option for Germline BRCA TNBC

For TNBC patients with a germline BRCA mutation, a completely chemotherapy-free neoadjuvant regimen using an oral PARP inhibitor is showing impressive pathologic complete response rates, potentially transforming the treatment paradigm for this genetically-defined subgroup.

S18 Ep33: Current Approaches and Future Directions for Early-Stage TNBC thumbnail

S18 Ep33: Current Approaches and Future Directions for Early-Stage TNBC

OncLive® On Air·2 months ago